NDA 020780 · Bayer Hlthcare
Cipro
Ciprofloxacin · Oral
Accelerated approvalLast checked: Nov 20, 2026Latest source record: Sep 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Sep 26, 1997
Approved uses
5
Original approval plus efficacy supplements
Registered trials
364
90 Phase 3, 32 recruiting
FAERS reports
97,364
81,282 serious, 9,759 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS • Fluoroquinolones, including CIPRO ® , have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions ( 5.1 )], including: • Tendinitis and tendon rupture [see Warnings and Precautions ( 5.2 )]. • Peripheral neuropathy [see Warnings and Precautions ( 5.3 )]. • Central nervous system effects [see Warnings and Precautions ( 5.4 )]. Discontinue CIPRO immediately and avoid the use of fluoroquinolones, including CIPRO, in patients who experience any of these serious adverse reactions [see Warnings and Precautions ( 5.1 )] . • Fluoroquinolones, including CIPRO, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid CIPRO in...
What it is approved for
From the label in effect Mar 2, 2026.
CIPRO is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: • Skin and Skin Structure Infections ( 1.1 ) • Bone and Joint Infections ( 1.2 ) • Complicated Intra-Abdominal Infections ( 1.3 ) • Infectious Diarrhea ( 1.4 ) • Typhoid Fever (Enteric Fever) ( 1.5 ) • Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) • Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7) • Plague in adult and pediatric patients ( 1.8 ) • Chronic Bacterial Prostatitis ( 1.9 ) • Lower Respiratory Tract Infections ( 1.10 ) • Acute Exacerbation of Chronic Bronchitis • Urinary Tract Infections ( 1.11 ) • Urinary Tract Infections (UTI) • Acute Uncomplicated Cystitis • Complicated UTI and Pyelonephritis in Pediatric Patients • Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO and other antibacterial drugs, CIPRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 ) 1.1 Skin and Skin Structure Infections CIPRO is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.2 Bone and Joint Infections CIPRO is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas...
Mechanism: Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology ( 12.4 )]. Mechanism of Action The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 2, 2015 Supplement 41 · Efficacy LabelLetter
- Jan 7, 2005 Supplement 16 · Efficacy LabelLetter
- Mar 25, 2004 Supplement 13 · Efficacy · priority review ReviewLetterLabel
- Aug 30, 2000 Supplement 8 · Efficacy · priority review ReviewLetterLabel
- Sep 26, 1997 Original approval · Type 3 - New Dosage Form
2 products under this application
- CIPRO · CIPROFLOXACIN 500MG/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
- CIPRO · CIPROFLOXACIN 250MG/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ciprofloxacin" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/SulfamethoxazolePivotal-lookingStatus unknown
Umeå UniversityAcademic, hospital or other
NCT02734732 · 2,800 participants (planned) · Start Apr 2015 · Primary completion Apr 2020
Drug: Trimethoprim/Sulfamethoxazole; Ciprofloxacin · For: Prostate Infection
Sites: Östersund, Sweden; Sundsvall, Sweden; Ängelholm, Sweden · 5 sites in all
- Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00014222 · 2,104 participants · Start Dec 4, 2000 · Primary completion Feb 10, 2014
Drug: epoetin alfa; filgrastim and 5 more · For: Breast Cancer
Sites: Fort Smith, Arkansas; Little Rock, Arkansas; La Jolla, California · 78 sites in all
University of WashingtonAcademic, hospital or other
NCT05286931 · 1,800 participants (planned) · Start Mar 3, 2022 · Primary completion Dec 31, 2025
Drug: Ciprofloxacin 500 mg · For: Neisseria Gonorrhoeae Infection
Sites: Seattle, Washington
- Antibiotic Prophylaxis Before Shock Wave LithotripsyPivotal-lookingCompleted
Clinical Urology and Epidemiology Working GroupGovernment (non-federal)
NCT03692715 · 1,732 participants · Start Sep 27, 2018 · Primary completion Dec 31, 2024
Drug: Ciprofloxacin; Placebo · For: Ureteral Stones; Ureteral Calculi; Nephrolithiasis
Sites: São Paulo, Brazil; London, Canada; Sherbrooke, Canada · 10 sites in all
- Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult WomenPivotal-lookingCompleted
Iterum Therapeutics, International LimitedIndustry
NCT03354598 · 1,671 participants · Start Aug 1, 2018 · Primary completion Jan 16, 2020
Drug: Sulopenem-Etzadroxil/Probenecid; Ciprofloxacin · For: Uncomplicated Urinary Tract Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Tolleson, Arizona · 60 sites in all
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02800785 · 1,552 participants · Start May 2016 · Primary completion Mar 5, 2020
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin · For: Appendicitis
Sites: Sylmar, California; Torrance, California; Aurora, Colorado · 25 sites in all
- Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.Pivotal-lookingCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT03228108 · 1,538 participants · Start Apr 3, 2018 · Primary completion Sep 26, 2021
Drug: Ciprofloxacin; Trimethoprim/Sulfamethoxazole and 2 more · For: Complication; Infection; Prostate Cancer
Sites: 's-Hertogenbosch, Netherlands; Arnhem, Netherlands; Bergen op Zoom, Netherlands · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity6,288
- pain6,189
- fatigue6,120
- nausea5,925
- diarrhoea5,915
- arthralgia5,639
- drug ineffective5,195
- dyspnoea4,813
- acute kidney injury4,798
- off label use4,695
- chronic kidney disease4,552
- vomiting4,503
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,014 |
| 2005 | 1,124 |
| 2006 | 1,306 |
| 2007 | 1,287 |
| 2008 | 1,819 |
| 2009 | 1,994 |
| 2010 | 2,250 |
| 2011 | 3,343 |
| 2012 | 3,228 |
| 2013 | 3,178 |
| 2014 | 3,522 |
| 2015 | 4,871 |
| 2016 | 6,922 |
| 2017 | 5,600 |
| 2018 | 8,113 |
| 2019 | 9,947 |
| 2020 | 7,219 |
| 2021 | 6,613 |
| 2022 | 5,320 |
| 2023 | 5,614 |
| 2024 | 5,347 |
| 2025 | 4,735 |
| 2026 | 2,989 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cipro (Ciprofloxacin)
2024 spending
$383K
Beneficiaries
1,807
2,197 claims
Per beneficiary
$212
$1.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $394,551 |
| 2021 | $415,820 |
| 2022 | $387,641 |
| 2023 | $396,416 |
| 2024 | $382,638 |
Part D: Cipro (Ciprofloxacin HCl)
2024 spending
$38K
Beneficiaries
273
401 claims
Per beneficiary
$141
$5.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $69,771 |
| 2021 | $55,411 |
| 2022 | $36,376 |
| 2023 | $28,560 |
| 2024 | $38,390 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.
Randremanana RV, Raberahona M, Bourner J, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis.
Hadidi MF, Alhamami N, Alhakami M, et al. · World J Urol 2024 · Systematic Review, Network Meta-Analysis
- Fluoroquinolones for treating tuberculosis.
Ziganshina LE, Vizel AA, Squire SB · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Fluoroquinolones for treating tuberculosis.
Ziganshina LE, Squire SB · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.
Dunne MW, Aronin SI, Das AF, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Antibiotics for preventing meningococcal infections.
Fraser A, Gafter-Gvili A, Paul M, et al. · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.